share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K:外國發行人報告
美股SEC公告 ·  09/06 08:19

Moomoo AI 已提取核心訊息

On September 6, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, and Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the publication of an international patent application for a novel MDMA-based combination treatment. This collaboration aims to enhance the safety and efficacy of treatments for mental health disorders and addictions by combining MDMA with N-Acylethanolamines, including Palmitoylethanolamide (PEA). SciSparc's CEO, Oz Adler, highlighted the significance of the collaboration in addressing FDA concerns regarding MDMA safety. The patent application is part of a broader research initiative between the two companies, which has resulted in thirteen patents filed to date. SciSparc is also involved in drug development programs for various central nervous system disorders and owns a controlling interest in a subsidiary selling hemp seed oil products. Clearmind's focus is on developing psychedelic-based compounds for health problems such as alcohol use disorder and holds nineteen patent families with 29 granted patents.
On September 6, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, and Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the publication of an international patent application for a novel MDMA-based combination treatment. This collaboration aims to enhance the safety and efficacy of treatments for mental health disorders and addictions by combining MDMA with N-Acylethanolamines, including Palmitoylethanolamide (PEA). SciSparc's CEO, Oz Adler, highlighted the significance of the collaboration in addressing FDA concerns regarding MDMA safety. The patent application is part of a broader research initiative between the two companies, which has resulted in thirteen patents filed to date. SciSparc is also involved in drug development programs for various central nervous system disorders and owns a controlling interest in a subsidiary selling hemp seed oil products. Clearmind's focus is on developing psychedelic-based compounds for health problems such as alcohol use disorder and holds nineteen patent families with 29 granted patents.
2024年9月6日,臨床階段的藥品公司SciSparc Ltd.與以幻覺藥爲療法重點的生物科技公司Clearmind Medicine Inc.宣佈了一項針對基於MDMA的新型組合治療的國際專利申請的發表。該合作旨在通過將MDMA與N-乙酰基乙醇胺(N-Acylethanolamines)相結合,包括棕櫚醇酰胺(Palmitoylethanolamide,PEA),來增強治療精神健康障礙和成癮症的安全性和有效性。SciSparc的首席執行官Oz Adler強調了這一合作在解決FDA對MDMA安全性方面的關注方面的重要性。專利申請是兩家公司之間更廣泛的研究計劃的一部分,到目前爲止已經取得十三項專利。SciSparc還參與了針對各種中樞神經系統障礙的藥物開發項目,並擁有一家銷售大麻籽油產品的子公司的控股權。Clearmind的重點是開發以幻覺物質爲基礎的化合物,用於解決諸如酒精使用障礙之類的健康問題,並擁有十九個專利族,共29項授權專利。
2024年9月6日,臨床階段的藥品公司SciSparc Ltd.與以幻覺藥爲療法重點的生物科技公司Clearmind Medicine Inc.宣佈了一項針對基於MDMA的新型組合治療的國際專利申請的發表。該合作旨在通過將MDMA與N-乙酰基乙醇胺(N-Acylethanolamines)相結合,包括棕櫚醇酰胺(Palmitoylethanolamide,PEA),來增強治療精神健康障礙和成癮症的安全性和有效性。SciSparc的首席執行官Oz Adler強調了這一合作在解決FDA對MDMA安全性方面的關注方面的重要性。專利申請是兩家公司之間更廣泛的研究計劃的一部分,到目前爲止已經取得十三項專利。SciSparc還參與了針對各種中樞神經系統障礙的藥物開發項目,並擁有一家銷售大麻籽油產品的子公司的控股權。Clearmind的重點是開發以幻覺物質爲基礎的化合物,用於解決諸如酒精使用障礙之類的健康問題,並擁有十九個專利族,共29項授權專利。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息